Rhodes Pharmaceutical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Rhodes Pharmaceutical is a private, commercial-stage generic drug manufacturer with a strategic focus on controlled substances, a complex and tightly regulated segment of the generics market. Its business model is centered on the development, manufacturing, and commercialization of generic products, positioning it to capitalize on cost-containment pressures in healthcare. While specific financials are not public, its established commercial operations and niche focus suggest it is a revenue-generating entity competing with other large generic manufacturers. The company's success hinges on its regulatory expertise, manufacturing capabilities, and ability to navigate the challenging patent and litigation landscape for generic drugs.

Pain ManagementCentral Nervous System Disorders

Technology Platform

Integrated capabilities in ANDA development and manufacturing for complex generics, with specialized expertise in DEA-controlled substance compliance, formulation science, bioequivalence testing, and Paragraph IV patent litigation.

Opportunities

The ongoing 'patent cliff' for brand-name drugs provides a steady stream of new targets for generic competition.

High regulatory barriers in the controlled substance segment can limit competition, offering potential for sustained margins on approved products.

Supply chain disruptions or competitor exits in this niche may create short-term supply opportunities for an established, compliant manufacturer.

Risk Factors

Intense price competition and consolidation among buyers create severe margin pressure across the generic drug industry.

The company faces extreme regulatory and litigation risk due to its focus on controlled substances and its historical affiliation with Purdue Pharma.

Patent litigation failures can lead to significant financial losses and delay product launches, undermining the core generic business model.

Competitive Landscape

Rhodes competes within the highly fragmented and competitive generic pharmaceutical industry, facing off against large global players like Teva, Sandoz (Novartis), and Mylan (now part of Viatris), as well as numerous other specialized generic companies. Its niche in controlled substances places it in competition with other firms having DEA-approved manufacturing capabilities, such as SpecGx (Mallinckrodt), Amneal Pharmaceuticals, and Hikma Pharmaceuticals. Competition is based on price, regulatory speed, manufacturing reliability, and success in patent litigation.

More companies in Small Molecule Drugs →More companies in United States →